The Federal Government, through the National Agency for the Control of AIDS (NACA), has joined global leaders to endorse a historic price reduction for a revolutionary HIV prevention drug, lenacapavir.

The landmark agreement, unveiled at the sidelines of the 80th United Nations General Assembly (UNGA) in New York during the Clinton Global Initiative (CGI) 2025 Annual Meeting, reduces the cost of the twice-yearly HIV prevention injection from $28,000 to just $40 per person per year.

She noted that the development will make the medicine accessible to millions across Nigeria and more than 100 low- and middle-income countries, adding that lenacapavir has been shown to be up to 100% effective in preventing new HIV infections.

Delivering Nigeria’s statement at the event, the Director General of NACA, Dr. Temitope Ilori, said that the cost reduction marks a milestone in the fight against HIV in Nigeria and globally.

“Through this landmark access agreement, we are unlocking affordable access to lenacapavir – a transformational new HIV prevention option that offers longer protection, greater convenience, and renewed hope to millions at risk. This agreement ensures that this breakthrough innovation does not remain a privilege for the few. It pairs innovation with equity, laying the foundation for broad, long-lasting impact for those who need it most.”

The announcement underscores Nigeria’s leadership role at the UNGA in shaping global health solutions and reaffirming its determination to expand access to prevention, strengthen health systems, and accelerate progress toward ending HIV as a public health threat by 2030.

The breakthrough was made possible through strong collaboration with UNITAID, the Clinton Health Access Initiative (CHAI), Wits RHI, Dr. Reddy’s Laboratories Ltd. (DRL), and the Gates Foundation.

Nigeria’s participation highlights the country’s resolve to harness innovation, deepen global partnerships, and secure a healthier and more resilient future for its people.